TG Therapeutics TGTX Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's pre-tax income?
- TG Therapeutics (TGTX) reported pre-tax income of $20.36M in Q1 2026.
- How has TG Therapeutics's pre-tax income changed year-over-year?
- TG Therapeutics's pre-tax income increased by 272.4% year-over-year, from $5.47M to $20.36M.
- What is the long-term trend for TG Therapeutics's pre-tax income?
- Over 3 years (2021 to 2025), TG Therapeutics's pre-tax income has grown at a -32.4% compound annual growth rate (CAGR), from -$348.1M to $107.39M.
- What does pre-tax income mean?
- The company's profit before accounting for income tax expenses.
- How do you interpret pre-tax income?
- Higher values indicate stronger operational performance and profitability before tax considerations.
- How does pre-tax income compare across companies?
- Standardized across all public companies, making it a primary benchmark for operational profitability.